Status
Ongoing
In collaboration with the European Society for Radiotherapy and Oncology (ESTRO), the Belgian Cancer Registry (BCR) is investigating the optimal use of radiotherapy for patients diagnosed with lung cancer between 2017 and 2019 in Belgium, both in general, and taking tumour type and stage into account.
ESTRO’s experts developed a decision tree to optimise use of radiotherapy in Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). To document the decision trees using Belgian figures, BCR uses cancer registration data and data on reimbursed medical benefits and medication obtained by the Agence InterMutualiste (AIM) (the agency responsible for collating data from Belgium’s seven health insurance funds).
The results will be discussed with experts from ESTRO and will be used as part of a European-level evaluation on the optimal use of radiotherapy.
ESTRO’s experts developed a decision tree to optimise use of radiotherapy in Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). To document the decision trees using Belgian figures, BCR uses cancer registration data and data on reimbursed medical benefits and medication obtained by the Agence InterMutualiste (AIM) (the agency responsible for collating data from Belgium’s seven health insurance funds).
The results will be discussed with experts from ESTRO and will be used as part of a European-level evaluation on the optimal use of radiotherapy.
Quality of care